Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VR 2076

Next Previous
Search
Drug Profile

VR 2076

Alternative Names: ICS/LABA/LAMA inhaled triple therapy - Vectura; LABA/LAMA/ICS inhaled triple therapy- Vectura; SKP 2076; VR2076

Latest Information Update: 28 Apr 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkyePharma PLC
  • Developer Mundipharma International; Vectura
  • Class Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 28 Apr 2019 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation, Aerosol)
  • 04 Jan 2018 Mundipharma stops the development of VR 2076 for Asthma and Chronic obstructive pulmonary disease
  • 23 Dec 2016 VR 2076 licensed to Mundipharma and an undisclosed US company for Asthma and Chronic obstructive pulmonary disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top